Key Points
- Jennifer Michaelson sold 8,000 shares on March 5 at an average price of $15.68 for $125,440, reducing her position by 4.47% to 170,844 shares; she has sold roughly 38,677 shares across multiple transactions since December.
- Shares opened at $15.31 (down 2.7%) with a market cap of about $904.5M and a 12‑month range of $5.68–$16.74, while analysts are mixed but the consensus rating is “Moderate Buy” with an average price target of $29.33.
- Institutional ownership is 86.31%, and several large funds (e.g., Lynx1, Blue Owl, State Street, Affinity) have recently increased their stakes in Cullinan.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $15.68, for a total value of $125,440.00. Following the completion of the sale, the insider owned 170,844 shares of the company's stock, valued at $2,678,833.92. This trade represents a 4.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jennifer Michaelson also recently made the following trade(s):
- On Wednesday, February 25th, Jennifer Michaelson sold 1,780 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.14, for a total transaction of $25,169.20.
- On Tuesday, February 24th, Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.47, for a total transaction of $52,106.47.
- On Monday, February 23rd, Jennifer Michaelson sold 1,752 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $13.99, for a total transaction of $24,510.48.
- On Friday, February 20th, Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.08, for a total transaction of $165,327.36.
- On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $5,004.48.
- On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.30, for a total transaction of $49,200.00.
- On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $10.01, for a total transaction of $13,463.45.
- On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $9.67, for a total transaction of $28,023.66.
- On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $11.90, for a total transaction of $11,840.50.
- On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.38, for a total value of $26,592.24.
Cullinan Therapeutics Trading Down 2.7%
Shares of CGEM opened at $15.31 on Tuesday. The firm has a market capitalization of $904.51 million, a P/E ratio of -4.63 and a beta of -0.16. The stock's fifty day simple moving average is $12.38 and its 200 day simple moving average is $9.78. Cullinan Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $16.74.
Analysts Set New Price Targets
Several equities research analysts have commented on CGEM shares. Wall Street Zen lowered Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, February 8th. New Street Research set a $26.00 price objective on Cullinan Therapeutics in a research note on Thursday, November 20th. Wedbush boosted their target price on Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an "outperform" rating in a report on Tuesday, December 9th. HC Wainwright increased their target price on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a "buy" rating in a research report on Thursday, January 8th. Finally, Zacks Research lowered shares of Cullinan Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 19th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.33.
Read Our Latest Analysis on Cullinan Therapeutics
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in CGEM. Lynx1 Capital Management LP lifted its stake in shares of Cullinan Therapeutics by 31.0% during the third quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company's stock worth $34,193,000 after purchasing an additional 1,365,248 shares in the last quarter. Blue Owl Capital Holdings LP grew its stake in shares of Cullinan Therapeutics by 5.2% in the third quarter. Blue Owl Capital Holdings LP now owns 2,510,972 shares of the company's stock valued at $14,890,000 after buying an additional 125,000 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Cullinan Therapeutics by 0.4% in the second quarter. Franklin Resources Inc. now owns 2,228,160 shares of the company's stock valued at $16,778,000 after buying an additional 8,399 shares in the last quarter. State Street Corp raised its holdings in shares of Cullinan Therapeutics by 31.0% during the 4th quarter. State Street Corp now owns 2,197,338 shares of the company's stock valued at $22,742,000 after buying an additional 520,024 shares during the period. Finally, Affinity Asset Advisors LLC raised its holdings in shares of Cullinan Therapeutics by 632.4% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company's stock valued at $19,997,000 after buying an additional 1,668,289 shares during the period. 86.31% of the stock is owned by hedge funds and other institutional investors.
Cullinan Therapeutics Company Profile
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
